MONTREAL, Feb. 28, 2013 /CNW Telbec/ - BIOQuébec is pleased to announce the appointment of Dr. Martin Godbout as chairman of the Board, replacing Mr. Gilles R. Gagnon, who held this position during the last 2 years. Mr. Godbout's appointment comes into force today. "Since its creation, BIOQuébec has played a key role as spokesperson of the biotechnology industry. It is with humility that I accept to collaborate, with all members of the Board, towards the development of strategies that will further the industry and promote the life sciences sector not only in Québec but abroad", stated Dr. Godbout. As director on BIOQuébec's Board for the last 2 years, Dr. Godbout also sits on several other Boards of biotechnology companies, foundations and Canadian scientific organizations. He is president of the MethylGene inc. and Génome Québec Boards and acts as director on the Boards of the following organizations: Acasti Pharma Inc., AmorChem Inc., AngioChem Inc., AsmaCure Inc., BioContact, the Fonds de recherche du Québec - santé (FQRS), Montréal In Vivo and the Fondation de l'Ataxie de Charlevoix. Dr. Godbout founded Génome Canada, and was its president and CEO for many years. Throughout his career, he sat on the Science and Technology Council of Québec and was a member of the Natural Sciences and Engineering Research Council of Canada. He also developed BioContact Québec, an annual symposium on biopharmaceutical partnerships. He held the position of senior vice-president of BioCapital, a major Canadian venture capital firm. Prior to this, he was CEO of Société Innovatech Québec, a technology investment fund. Dr. Godbout is an Officer of the Order of Canada and has received numerous awards in Canada and abroad. BIOQuébec's Board of Directors would like to thank Mr. Gagnon for his contribution to the association and wishes him much luck in his future projects. About BIOQuébec BIOQuébec is a biotechnology and life science industry association representing nearly 100 member companies and R&D centres in Québec. The association works to create a positive business environment which fosters the growth of the life science industry, including access to capital and access to development and marketing partners, workforce development, a regulatory and competitive tax environment and the promotion of its members among various publics both in Québec and on an international level. Board of Directors 2012-2013 -- Dr. Martin Godbout President of the Board Corporate Director Hodran Consultants Inc. -- Mario Lebrun General Manager BIOQuébec -- Michel Fortin Secretary-Treasurer CEO Prevtec microbia inc. -- John-Michel T. Huss Vice-President Corporate Director -- Yves Roy Vice-President President Corealis Pharma Inc. -- Andy Sheldon Vice-President CEO Medicago Inc. -- Cédric Bisson Venture Partner Teralys Capital Inc. -- Jean-Paul Castaigne CEO Angiochem Inc. -- Richard Cherney Managing Partner Davies Ward Phillips & Vineberg, s.r.l. -- Claude Chevalier CEO BIO-K + International Inc. -- Pierre Falardeau CEO Oncozyme Pharma Inc. -- Jean Godin Chief Scientific Officer Novartis Pharma Canada Inc. -- Charles Grubsztajn Corporate Director -- Dr. Pavel Hamet President Medpharmgene Inc. -- Grant Perry Vice-President, Public Affairs and Reimbursement GlaxoSmithKline Inc. -- Louise Proulx Corporate Director Mario Lebrun BIOQuébec General Manager 450-781-3965 email@example.com SOURCE: BIOQUEBEC To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2013/28/c9067.html CO: BIOQUEBEC ST: Quebec NI: BTC 2575 WNEWS -0- Feb/28/2013 14:00 GMT
BIOQuébec Appoints a New Chairman of the Board
Press spacebar to pause and continue. Press esc to stop.